https://www.marketscreener.com/quote/stock/SEAGEN-INC-10808/news/Seattle-Genetics-Initiates-Pivotal-Phase-3-Trial-of-Vadastuximab-Talirine-SGN-CD33A-for-Patients-22417661/?utm_source=telegram&utm_medium=social&utm_campaign=share